Comparative Pharmacology
Head-to-head clinical analysis: PHENOXYBENZAMINE HYDROCHLORIDE versus PHENTOLAMINE MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENOXYBENZAMINE HYDROCHLORIDE versus PHENTOLAMINE MESYLATE.
PHENOXYBENZAMINE HYDROCHLORIDE vs PHENTOLAMINE MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenoxybenzamine hydrochloride is a nonselective, irreversible alpha-adrenergic antagonist. It blocks both alpha-1 and alpha-2 receptors, leading to vasodilation, decreased peripheral vascular resistance, and relaxation of smooth muscle in the bladder neck and prostate.
Phentolamine mesylate is a non-selective competitive alpha-adrenergic antagonist (blocks alpha-1 and alpha-2 receptors), leading to vasodilation and decreased peripheral vascular resistance. It also antagonizes serotonin and produces direct vasodilation and positive inotropic and chronotropic effects.
10 mg orally twice daily, increase by 10 mg every 4 days to a maximum of 240 mg/day in divided doses.
5 mg intravenous or intramuscular, 1-2 hours before surgery for pheochromocytoma; for hypertensive crisis: 5-20 mg intravenous bolus, repeated as needed.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours (range 12–48 hours), allowing once-daily dosing after titration. Clinical context: Steady-state is reached in 4–5 days.
Terminal elimination half-life is approximately 19 minutes; short half-life necessitates continuous or repeated dosing for sustained alpha-blockade.
Primarily renal (approximately 50% as unchanged drug and metabolites); biliary/fecal excretion accounts for a minor portion (<10%).
Renal (approximately 10% unchanged); remainder metabolized in liver with metabolites excreted renally and in feces via bile.
Category C
Category C
Alpha Blocker
Alpha Blocker